Australian Government
Department of Health, Disability and Ageing
Office of the Gene Technology Regulator

NOTIFICATION OF APPLICATION

Receipt of licence application from Intervet Australia Pty Ltd for Commercial supply of multivalent cat vaccines containing a genetically modified component for the prevention of feline leukemia virus infection

The Office of the Gene Technology Regulator (OGTR) has received a licence application (DIR 220) from Intervet Australia Pty Ltd (Intervet) for commercial supply of cat vaccines containing a GM component for the prevention of feline leukemia virus (FeLV) infection. A summary of the application and a Questions and Answers document is available on our website (search for DIR 220).

Intervet is seeking approval for the import, transport, storage, and disposal of the vaccines. If also approved by the Australian Pesticide and Veterinary Medicines Authority, the vaccines would be commercially supplied to veterinary clinics for vaccination of cats.

The OGTR is preparing a Risk Assessment and Risk Management Plan (RARMP) for the application. The RARMP will be prepared taking into account advice received from a broad range of experts, agencies and authorities, and relevant local councils, as specified in the *Gene Technology Act 2000*. This is expected to be released for public comment and advice from experts, agencies and authorities in **April 2026.** There will be at least 30 days for submission of comments.

If you have any questions or would like to receive a copy of the application or the summary, please contact the OGTR and quote the reference number DIR 220.

Office of the Gene Technology Regulator **MDP 54 GPO Box 9848 CANBERRA ACT 2601**
Telephone: 1800 181 030 **E-mail: ogtr@health.gov.au**
OGTR website

Dr Raj Bhula
Gene Technology Regulator
29 October 2025